Abstract
Studies have reported that B- and T-lymphocyte attenuator (BTLA) polymorphisms may be associated with the risk to different cancers. However, the correlation between those variations and non-small-cell lung cancer (NSCLC) is still unclear. A total of 1,003 NSCLC patients and 901 noncancer controls were recruited in the study, to confirm the association of variations in BTLA gene with the risk of NSCLC. The SNPscan™ genotyping assay was used to obtain the genotypes of the four BTLA polymorphisms (BTLA rs1982809 G>A, rs16859629 T>C, rs2171513 G>A, and rs3112270 A>G). It was found that BTLA rs1982809 polymorphism reduced the risk of NSCLC (GA vs. GG: adjusted odds ratio (OR) = 0.81, 95%confidence interval (CI) = 0.66‐0.99, and P = 0.043). However, the BTLA rs16859629, rs2171513, and rs3112270 polymorphisms showed no significant association between NSCLC patients and controls in overall comparison. In subgroup analyses, we found that BTLA rs1982809 polymorphism reduced the risk of NSCLC (nonsquamous cell carcinoma: GA vs. GG: adjusted OR = 0.79, 95%CI = 0.64‐0.97, and P = 0.026; AA/GA vs. GG: adjusted OR = 0.81, 95%CI = 0.66‐0.99, and P = 0.037; ≥59 years: GA vs. GG: P = 0.036; never alcohol consumption: GA vs. GG: P = 0.013; GA/AA vs. GG: P = 0.016; body mass index (BMI) ≥ 24 kg/m2: GA vs. GG: P = 0.030; GA/AA vs. GG: P = 0.041). The BTLA rs16859629 polymorphism increased the risk of the development of squamous cell carcinoma (CC vs. TT: adjusted OR = 9.85, 95%CI = 1.37‐71.03, and P = 0.023; CC vs. TT/TC: adjusted OR = 9.55, 95%CI = 1.32‐68.66, and P = 0.025). Taken together, the findings of the present suggest that BTLA rs1982809 and rs16859629 polymorphisms may influence the susceptibility to NSCLC in the Chinese population.
Highlights
Non-small-cell lung cancer (NSCLC) accounts for 80 to 85% of all the lung cancer and is the main pathological type of lung cancer (LC)
We reported that B- and T-lymphocyte attenuator (BTLA) rs1982809 Single nucleotide polymorphism (SNP) increased the susceptibility of esophagogastric junction adenocarcinoma (EGJA) in smoking subgroup analyses [18]
We found that the BTLA rs3112270 A>G and rs2171513 G>A polymorphisms could modify the risk of esophageal squamous cell carcinoma (ESCC) [19]
Summary
Non-small-cell lung cancer (NSCLC) accounts for 80 to 85% of all the lung cancer and is the main pathological type of lung cancer (LC). LC has imposed huge diseases burden on human population and accounts for significant number of mortalities across the globe [1,2,3]. LC is currently ranked as first in terms of incidence and mortality [4]. The currently used treatment strategies for LC include surgery combined with adjuvant therapy. Owing to the recent advancements made in the diagnosis and treatment, the clinical outcomes have significantly improved [5]. The identification of the potential risk factors for the occurrence of LC is considered essential as it will permit early diagnosis and immediate management
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
